ERBB2 and breast cancer: Median overall survival (OS) in patients with MBC is approximately 37 months, with better results reported by women with hormone receptor positive (HR+) and human epidermal receptor 2 positive (HER2+) tumors (42.12 and 44.91 months, respectively) as compared with those with triple-negative BC (TNBC: 14.52 months) [4].